Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.

@article{Yang2011RadiosensitizationOH,
  title={Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.},
  author={Jie Yang and Donna McEachern and Wenyan Li and Mary Alice Davis and Hua Li and M. A. Morgan and Longchuan Bai and Jonathan T Sebolt and Haiying Sun and Theodore Steven Lawrence and Shaomeng Wang and Yi Mike Sun},
  journal={Molecular cancer therapeutics},
  year={2011},
  volume={10 4},
  pages={658-69}
}
Chemoradiation is the treatment of choice for locally advanced head and neck squamous cell carcinoma (HNSCC). However, radioresistance, which contributes to local recurrence, remains a significant therapeutic problem. In this study, we characterized SM-164, a small second mitochondria-derived activator of caspase -mimetic compound that promotes degradation of cellular inhibitor of apoptosis-1(cIAP-1; also known as baculoviral IAP repeat-containing protein 2, BIRC2) and releases active caspases… CONTINUE READING